Meningitis charity hopeful life saving vaccine will be introduced in Ireland
02 April 2014
Campaigning charity Meningitis Research Foundation Ireland welcomes the news that the National Immunisation Advisory Committee (NIAC) is making a vaccine for meningococcal disease group B (MenB) a priority issue for careful consideration, following a recommendation to introduce the life saving vaccine in the UK.
NIAC’s statement follows news that its UK equivalent, the Joint Committee on Vaccination and Immunisation has recommended the vaccine for infants in three doses ages 2, 4 and 12 months. NIAC says it discussed introducing MenB into its primary immunisation programme at its meeting on 24 March and is seeking more information before making its recommendation.
Meningitis Research Foundation Manager Diane McConnell said: “MenB kills and disables more children in Ireland than any other infectious disease. That’s why this charity and our supporters have campaigned so hard for this vaccine. We applaud the decision taken by the JCVI, which means children in Northern Ireland will be protected from this deadly disease, and are hopeful that NIAC will also recognise the importance of this vaccine and introduce it here too.”
The MenB vaccine under consideration by NIAC is called Bexsero® and is produced by Novartis Vaccines. It was licensed by the European Union in January 2013.
More on MenB
In-depth Q + A on the vaccine